Temoporfin
Based on 12 publication(s) in Google Scholar
Temoporfin (m-THPC), a reduced porphyrin, is a potent second-generation photosensitizer. Temoporfin can be used in the research of photodynamic therapy (PDT) for head and neck cancers.
For research use only. We do not sell to patients.
- Purity: 97.34%
- CAS No.: 122341-38-2
- Formula: C44H32N4O4
- Molecular Weight:680.75
-
Storage:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Cancer Approved Drug Library
HY-L213
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Temoporfin
More- Nucleic Acids Res. 2023 Jul 7;51(12):6264-6285. [Abstract]
- Theranostics. 2018 Feb 4;8(5):1435-1448. [Abstract]
- Cell Death Dis. 2020 Oct 31;11(10):938. [Abstract]
- Pharmaceutics. 2023 Nov 28;15(12):2694. [Abstract]
- Biomacromolecules. 2024 Sep 9;25(9):5771-5785. [Abstract]
- Cancers (Basel). 2022 May 31;14(11):2724. [Abstract]
- Photodiagnosis Photodyn Ther. 2025 Mar 22:104564. [Abstract]
- Am J Transl Res. 2020 Sep 15;12(9):5080-5094. [Abstract]
- Chemrxiv. 2025 Aug 28.
- Biomed Pharmacother. 2024 May 24:176:116768. [Abstract]
- SSRN. 2023 Jan 26.
- Research Square Preprint. 2022 Jul.
Customer Validation & Images
-
IF
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 4T1 | IC50 |
117 nM
Compound: m-THPC
|
Phototoxicity against mouse 4T1 cells on exposure to 13.3 J/cm'2 light after 16 hrs by Trypan blue exclusion method
Phototoxicity against mouse 4T1 cells on exposure to 13.3 J/cm'2 light after 16 hrs by Trypan blue exclusion method
|
[PMID: 18788727] |
| 4T1 | IC50 |
0.05 μM
Compound: Temoporfin
|
Phototoxicity against mouse 4T1 cells assessed as reduction in cell viability preincubated for 4 hrs followed by irradiation with 0.3 W/cm2 of 625 +/- 2 nanometer LED light for 1 hr and measured after 42 hrs by MTT assay
Phototoxicity against mouse 4T1 cells assessed as reduction in cell viability preincubated for 4 hrs followed by irradiation with 0.3 W/cm2 of 625 +/- 2 nanometer LED light for 1 hr and measured after 42 hrs by MTT assay
|
[PMID: 32916313] |
| 4T1 | IC50 |
38.01 μM
Compound: Temoporfin
|
Dark toxicity in mouse 4T1 cells assessed as reduction in cell viability by MTT assay
Dark toxicity in mouse 4T1 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 32916313] |
| A549 | IC50 |
0.702 μM
Compound: m-THPC
|
Photodynamic cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs followed by compound washout and subsequent 650 nanometer laser light irradiation at 2 J/cm2 measured by MTT assay
Photodynamic cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs followed by compound washout and subsequent 650 nanometer laser light irradiation at 2 J/cm2 measured by MTT assay
|
[PMID: 31132530] |
| A549 | IC50 |
0.779 μM
Compound: m-THPC
|
Photodynamic cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs followed by compound washout and subsequent 650 nanometer laser light irradiation at 1 J/cm2 measured by MTT assay
Photodynamic cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs followed by compound washout and subsequent 650 nanometer laser light irradiation at 1 J/cm2 measured by MTT assay
|
[PMID: 31132530] |
| A549 | IC50 |
1.099 μM
Compound: m-THPC
|
Photodynamic cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs followed by compound washout and subsequent 650 nanometer laser light irradiation at 0.5 J/cm2 measured by MTT assay
Photodynamic cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs followed by compound washout and subsequent 650 nanometer laser light irradiation at 0.5 J/cm2 measured by MTT assay
|
[PMID: 31132530] |
| A549 | CC50 |
40.7 μM
Compound: 40
|
Cytotoxicity against human A549 cells incubated for 42 hrs by MTT assay
Cytotoxicity against human A549 cells incubated for 42 hrs by MTT assay
|
[PMID: 34458734] |
| HCT-116 | IC50 |
5.17 ng/mL
Compound: temoporfin
|
Cytotoxicity against human HCT116 cell line
Cytotoxicity against human HCT116 cell line
|
[PMID: 16722648] |
| HCT-116 | IC50 |
7.6 nM
Compound: temoporfin
|
Cytotoxicity against human HCT116 cell line
Cytotoxicity against human HCT116 cell line
|
[PMID: 16722648] |
| HCT-116 | IC50 |
40.95 nM
Compound: m-THPC, temoporfin
|
Phototoxicity against human HCT116 cells assessed as nitrite accumulation after 24 hrs irradiated with LED red light for 2 hrs followed by incubation in drug free medium for 24 hrs by MTT assay
Phototoxicity against human HCT116 cells assessed as nitrite accumulation after 24 hrs irradiated with LED red light for 2 hrs followed by incubation in drug free medium for 24 hrs by MTT assay
|
[PMID: 19211252] |
| HCT-116 | IC50 |
7.6 nM
Compound: m-THPC, temoporfin
|
Phototoxicity against human HCT116 cells after 24 hrs irradiated with tungsten-halogen white light for 2 hrs followed by incubation in drug free medium for 24 hrs by MTT assay
Phototoxicity against human HCT116 cells after 24 hrs irradiated with tungsten-halogen white light for 2 hrs followed by incubation in drug free medium for 24 hrs by MTT assay
|
[PMID: 19211252] |
| HL-60 | IC50 |
42 nM
Compound: m-THPC
|
Phototoxicity against human HL60 cells on exposure to 13.3 J/cm'2 light after 16 hrs by Trypan blue exclusion method
Phototoxicity against human HL60 cells on exposure to 13.3 J/cm'2 light after 16 hrs by Trypan blue exclusion method
|
[PMID: 18788727] |
| HUVEC | IC50 |
>100 μM
Compound: Temoporfin
|
Dark toxicity in HUVEC assessed as reduction in cell viability by MTT assay
Dark toxicity in HUVEC assessed as reduction in cell viability by MTT assay
|
[PMID: 32916313] |
| HUVEC | IC50 |
1.5 μM
Compound: Temoporfin
|
Phototoxicity against HUVEC assessed as reduction in cell viability preincubated for 4 hrs followed by irradiation with 0.3 W/cm2 of 625 +/- 2 nanometer LED light for 1 hr and measured after 42 hrs by MTT assay
Phototoxicity against HUVEC assessed as reduction in cell viability preincubated for 4 hrs followed by irradiation with 0.3 W/cm2 of 625 +/- 2 nanometer LED light for 1 hr and measured after 42 hrs by MTT assay
|
[PMID: 32916313] |
| MDA-MB-231 | IC50 |
0.87 μM
Compound: Temoporfin
|
Phototoxicity against human MDA-MB-231 cells assessed as reduction in cell viability preincubated for 4 hrs followed by irradiation with 0.3 W/cm2 of 625 +/- 2 nanometer LED light for 1 hr and measured after 42 hrs by MTT assay
Phototoxicity against human MDA-MB-231 cells assessed as reduction in cell viability preincubated for 4 hrs followed by irradiation with 0.3 W/cm2 of 625 +/- 2 nanometer LED light for 1 hr and measured after 42 hrs by MTT assay
|
[PMID: 32916313] |
| MDA-MB-231 | IC50 |
33.42 μM
Compound: Temoporfin
|
Dark toxicity in human MDA-MB-231 cells assessed as reduction in cell viability by MTT assay
Dark toxicity in human MDA-MB-231 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 32916313] |
A detailed confocal fluorescence microscopy study of a human adenocarcinoma shows weak localization of Temoporfin in lysosomes and mitochondria. Instead, it is found to be localized in the endoplasmic reticulum (ER) and the Golgi apparatus[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 122341-38-2
-
Appearance Solid
-
Molecular Weight 680.75
-
Formula C44H32N4O4
-
Color Purple to black
-
SMILES
OC1=CC=CC(/C2=C3CCC(/C(C4=CC(O)=CC=C4)=C5C=C/C(N/5)=C(C6=CC(O)=CC=C6)/C(C=C/7)=NC7=C(C8=CC(O)=CC=C8)/C9=CC=C2N9)=N\3)=C1
-
Synonyms
m-THPC; KW2345
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Nucleic Acids Res
A new G-quadruplex-specific photosensitizer inducing genome instability in cancer cells by triggering oxidative DNA damage and impeding replication fork progression. [Abstract]2023 Jul 7;51(12):6264-6285. PMID: 37191066 -
Theranostics
Targeted Delivery of Functionalized Upconversion Nanoparticles for Externally Triggered Photothermal/Photodynamic Therapies of Brain Glioblastoma. [Abstract]2018 Feb 4;8(5):1435-1448. PMID: 29507632
Temoporfin purchased from MedChemExpress. Usage Cited in: Theranostics. 2018 Feb 4;8(5):1435-1448. [Abstract]
In vivo fluorescence images of glioma-bearing mice intravenously receiving different mTHPC-containing formulations.
-
Cell Death Dis
Photodynamic therapy induces autophagy-mediated cell death in human colorectal cancer cells via activation of the ROS/JNK signaling pathway. [Abstract]2020 Oct 31;11(10):938. PMID: 33130826 -
Pharmaceutics
Temoporfin-Conjugated Upconversion Nanoparticles for NIR-Induced Photodynamic Therapy: Studies with Pancreatic Adenocarcinoma Cells In Vitro and In Vivo. [Abstract]2023 Nov 28;15(12):2694. PMID: 38140035 -
Biomacromolecules
Temoporfin-Conjugated PEGylated Poly(N, N-dimethylacrylamide)-Coated Upconversion Colloid for NIR-Induced Photodynamic Therapy of Pancreatic Cancer. [Abstract]2024 Sep 9;25(9):5771-5785. PMID: 38888278 -
Cancers (Basel)
Photodynamic Therapy in Combination with the Hepatitis B Core Virus-like Particles (HBc VLPs) to Prime Anticancer Immunity for Colorectal Cancer Treatment. [Abstract]2022 May 31;14(11):2724. PMID: 35681703 -
Photodiagnosis Photodyn Ther
Assessment of bimodal laser photodynamic therapy at wavelenths of 410 nm and 653 nm for oral precancerous lesions: An in vitro and in vivo study. [Abstract]2025 Mar 22:104564. PMID: 40127707 -
Am J Transl Res
Chlorin A-mediated photodynamic therapy induced apoptosis in human cholangiocarcinoma cells via impaired autophagy flux. [Abstract]2020 Sep 15;12(9):5080-5094. PMID: 33042407 -
-
Biomed Pharmacother
2024 May 24:176:116768. PMID: 38795638 -
-
Solvent & Solubility
DMSO : 20.83 mg/mL (30.60 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (1.47 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL (1.47 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
-
Handling Instructions (2659 KB)
References
[1]. Senge MO, et, al. Temoporfin (Foscan®, 5,10,15,20-tetra(m-hydroxyphenyl)chlorin)--a second-generation photosensitizer. Photochem Photobiol. 2011 Nov-Dec;87(6):1240-96. [Content Brief]
[2]. Rovers JP, et, al. Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model. Br J Cancer. 1999 Oct;81(4):600-8. [Content Brief]
[3]. Reshetov V, et, al. Photodynamic therapy with conventional and PEGylated liposomal formulations of mTHPC (temoporfin): comparison of treatment efficacy and distribution characteristics in vivo. Int J Nanomedicine. 2013;8:3817-31. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4690 mL | 7.3448 mL | 14.6897 mL | 36.7242 mL |
| 5 mM | 0.2938 mL | 1.4690 mL | 2.9379 mL | 7.3448 mL | |
| 10 mM | 0.1469 mL | 0.7345 mL | 1.4690 mL | 3.6724 mL | |
| 15 mM | 0.0979 mL | 0.4897 mL | 0.9793 mL | 2.4483 mL | |
| 20 mM | 0.0734 mL | 0.3672 mL | 0.7345 mL | 1.8362 mL | |
| 25 mM | 0.0588 mL | 0.2938 mL | 0.5876 mL | 1.4690 mL | |
| 30 mM | 0.0490 mL | 0.2448 mL | 0.4897 mL | 1.2241 mL |
Temoporfin Related Classifications
HY-16488 Related Classifications
Powered by Bioz